Skip to content

Study · Observational study · 2025

11 results

Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.

Oya J, Shimizu M, Kubota R, Suda R, Nagkagami T

Journal of diabetes investigation20 Dec 2024

PMID39707717 (opens in a new tab)PMCIDPMC11970300 (opens in a new tab)DOI10.1111/jdi.14391 (opens in a new tab)PepBankPUB-39707717
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In incretin-naïve participants with T2DM, HbA1c decreased after oral semaglutide versus baseline.

    In plain wordsIn participants with diabetes and no prior incretin treatment, oral semaglutide was linked to lower HbA1c than baseline.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change in incretin-naïve participants
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.85%
    naïve
    Lower confidence limit
    −1.08%
    95% CI
    Upper confidence limit
    −0.62%
    95% CI

    Source sentences

    Summary
    Mean change of HbA1c in DPP-4i and GLP-1 RA groups was -0.67% (95% confidence interval [CI]: -0.79 to -0.54) and -0.13% (95% CI: -0.40 to 0.15), respectively, which were significantly smaller than incretin-related drug-naïve group; -0.85% (95% CI: -1.08 to -0.62).
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  2. 02HumanObservational studyEfficacy outcome

    In participants switching from DPP-4 inhibitors to oral semaglutide, HbA1c decreased versus baseline.

    In plain wordsIn participants with diabetes, switching from DPP-4 inhibitors to oral semaglutide was linked to lower HbA1c than baseline.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change after DPP-4 inhibitor switch
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.67%
    DPP-4i
    Lower confidence limit
    −0.79%
    95% CI
    Upper confidence limit
    −0.54%
    95% CI

    Source sentences

    Summary
    Mean change of HbA1c in DPP-4i and GLP-1 RA groups was -0.67% (95% confidence interval [CI]: -0.79 to -0.54) and -0.13% (95% CI: -0.40 to 0.15), respectively, which were significantly smaller than incretin-related drug-naïve group; -0.85% (95% CI: -1.08 to -0.62).
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  3. 03HumanObservational studyEfficacy outcome

    In participants switching from GLP-1RAs to oral semaglutide, HbA1c change had a confidence interval spanning zero.

    In plain wordsIn participants with diabetes, switching from GLP-1RAs to oral semaglutide showed no clear HbA1c change from baseline.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c change after GLP-1RA switch
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.13%
    GLP-1RA
    Lower confidence limit
    −0.4%
    95% CI
    Upper confidence limit
    0.15%
    95% CI

    Source sentences

    Summary
    Mean change of HbA1c in DPP-4i and GLP-1 RA groups was -0.67% (95% confidence interval [CI]: -0.79 to -0.54) and -0.13% (95% CI: -0.40 to 0.15), respectively, which were significantly smaller than incretin-related drug-naïve group; -0.85% (95% CI: -1.08 to -0.62).
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  4. 04HumanObservational studyEfficacy outcome

    In participants with T2DM, HbA1c reduction after oral semaglutide was smaller after DPP-4 inhibitor switching than in incretin-naïve participants.

    In plain wordsWith oral semaglutide, prior DPP-4 inhibitor users had smaller HbA1c reductions than participants without prior incretin treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction after DPP-4i versus naïve
    Study

    n: not reported in source

    Comparator
    Incretin-naïve participants receiving oral semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.67%
    DPP-4i
    Lower confidence limit
    −0.79%
    DPP-4i 95% CI
    Upper confidence limit
    −0.54%
    DPP-4i 95% CI
    HbA1c change
    −0.85%
    naïve
    Lower confidence limit
    −1.08%
    naïve 95% CI
    Upper confidence limit
    −0.62%
    naïve 95% CI

    Source sentences

    Summary
    Mean change of HbA1c in DPP-4i and GLP-1 RA groups was -0.67% (95% confidence interval [CI]: -0.79 to -0.54) and -0.13% (95% CI: -0.40 to 0.15), respectively, which were significantly smaller than incretin-related drug-naïve group; -0.85% (95% CI: -1.08 to -0.62).
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  5. 05HumanObservational studyEfficacy outcome

    In participants with T2DM, HbA1c reduction after oral semaglutide was smaller after GLP-1RA switching than in incretin-naïve participants.

    In plain wordsWith oral semaglutide, prior GLP-1RA users had smaller HbA1c reductions than participants without prior incretin treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction after GLP-1RA versus naïve
    Study

    n: not reported in source

    Comparator
    Incretin-naïve participants receiving oral semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.13%
    GLP-1RA
    Lower confidence limit
    −0.4%
    GLP-1RA 95% CI
    Upper confidence limit
    0.15%
    GLP-1RA 95% CI
    HbA1c change
    −0.85%
    naïve
    Lower confidence limit
    −1.08%
    naïve 95% CI
    Upper confidence limit
    −0.62%
    naïve 95% CI

    Source sentences

    Summary
    Mean change of HbA1c in DPP-4i and GLP-1 RA groups was -0.67% (95% confidence interval [CI]: -0.79 to -0.54) and -0.13% (95% CI: -0.40 to 0.15), respectively, which were significantly smaller than incretin-related drug-naïve group; -0.85% (95% CI: -1.08 to -0.62).
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  6. 06HumanObservational studyEfficacy outcome

    In participants with T2DM, body weight change after oral semaglutide did not differ between DPP-4 inhibitor switchers and incretin-naïve participants.

    In plain wordsWith oral semaglutide, weight changes were similar between prior DPP-4 inhibitor users and participants without prior incretin treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody weight change after DPP-4i versus naïve
    Study

    n: not reported in source

    Comparator
    Incretin-naïve participants receiving oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Mean change in BW between the naïve and DPP-4i groups had no differences; however, these changes were lower in the GLP-1 RA group than in the naïve group.
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  7. 07HumanObservational studyEfficacy outcome

    In participants with T2DM, body weight changes after oral semaglutide were lower in prior GLP-1RA users than in incretin-naïve participants.

    In plain wordsWith oral semaglutide, weight changes were lower in prior GLP-1RA users than in participants without prior incretin treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change after GLP-1RA versus naïve
    Study

    n: not reported in source

    Comparator
    Incretin-naïve participants receiving oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Mean change in BW between the naïve and DPP-4i groups had no differences; however, these changes were lower in the GLP-1 RA group than in the naïve group.
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  8. 08HumanObservational studyEfficacy outcome

    In participants switching to oral semaglutide, HbA1c changes did not differ by previous GLP-1RA treatment.

    In plain wordsAfter switching to oral semaglutide, HbA1c changes were similar across previous GLP-1RA treatments.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c change by previous GLP-1RA
    Study

    n: not reported in source

    Comparator
    Other previous GLP-1RA treatments
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Mean change in HbA1c between pretreatment with GLP-1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group.
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.
  9. 09HumanObservational studyEfficacy outcome

    After oral semaglutide switching, mean body weight change was higher in prior dulaglutide users than in prior injectable semaglutide users.

    In plain wordsAfter switching to oral semaglutide, weight change was higher in prior dulaglutide users than in prior injectable semaglutide users.

    Peptide
    Semaglutide
    Outcome
    IncreaseBody weight change by prior dulaglutide versus injectable semaglutide
    Study

    n: not reported in source

    Comparator
    Previous injectable semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Mean change in HbA1c between pretreatment with GLP-1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group.
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In participants switching to oral semaglutide, HbA1c changes did not differ by previous GLP-1RA treatment, including dulaglutide.

    In plain wordsAfter switching to oral semaglutide, HbA1c changes were similar across previous GLP-1RA treatments, including dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c change after switching by previous GLP-1RA
    Study

    n: not reported in source

    Comparator
    Other previous GLP-1RA treatments
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Mean change in HbA1c between pretreatment with GLP-1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group.
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After oral semaglutide switching, mean body weight change was higher in prior dulaglutide users than in prior injectable semaglutide users.

    In plain wordsAfter switching to oral semaglutide, weight change was higher in prior dulaglutide users than in prior injectable semaglutide users.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBody weight change after switch to oral semaglutide
    Study

    n: not reported in source

    Comparator
    Previous injectable semaglutide
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Mean change in HbA1c between pretreatment with GLP-1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group.
    2 context sentences
    Summary · context
    A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin-related drug-naïve (naïve), switching from dipeptidyl peptide-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonist (GLP-1 RA) groups.
    Summary · context
    Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.